Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Keefe · SciRah

Researcher profile · Semantic Scholar

S. Keefe

Share profile

S. Keefe — researcher profile on SciRah

h-index: 30
Works: 108
Citations: 5,208

Most-cited papers

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
A. Balar, D. Castellano, P. O'Donnell, P. Grivas +11 more
2017The Lancet Oncology1,162 citations
Semantic Scholar
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
N. Colombo, C. Dubot, D. Lorusso, M. V. Cáceres +15 more
2021New England Journal of Medicine887 citations Open access
Semantic Scholar
Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.
U. Matulonis, R. Shapira-Frommer, A. Santin, A. Lisyanskaya +17 more
2019Annals of Oncology743 citations Open access
Semantic Scholar
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
A. Hansen, C. Massard, P. Ott, N. Haas +10 more
2018Annals of Oncology324 citations Open access
Semantic Scholar
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
Bradley J. Monk, N. Colombo, K. Tewari, C. Dubot +14 more
2023Journal of Clinical Oncology225 citations Open access
Semantic Scholar
Management of sorafenib-related adverse events: a clinician's perspective.
M. Brose, C. Frenette, S. Keefe, S. Stein
2014Seminars in Oncology133 citations Open access
Semantic Scholar
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.
J. Weber, Laura A. Levit, P. Adamson, S. Bruinooge +10 more
2015Journal of Clinical Oncology104 citations Open access
Semantic Scholar
Bladder preservation in the treatment of muscle‐invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy
Z. Smith, J. Christodouleas, S. Keefe, S. Malkowicz +1 more
2013BJU International83 citations
Semantic Scholar
Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
R. Mamtani, N. Pfanzelter, K. Haynes, B. Finkelman +5 more
2014Diabetes Care74 citations Open access
Semantic Scholar
Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma
V. Narayan, S. Keefe, N. Haas, Le Wang +13 more
2017Clinical Cancer Research70 citations Open access
Semantic Scholar
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses from the KEYNOTE-826 Randomized Clinical Trial.
K. Tewari, N. Colombo, B. Monk, C. Dubot +15 more
2023JAMA Oncology67 citations Open access
Semantic Scholar
Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
A. Balar, J. Bellmunt, P. O'Donnell, D. Castellano +11 more
201667 citations Open access
Semantic Scholar
The molecular biology of renal cell carcinoma.
S. Keefe, K. Nathanson, W. Rathmell
2013Seminars in Oncology60 citations
Semantic Scholar
Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).
P. O'Donnell, P. Grivas, A. Balar, J. Bellmunt +11 more
201759 citations
Semantic Scholar
Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.
A. Balar, D. Castellano, P. O'Donnell, P. Grivas +11 more
201754 citations
Semantic Scholar
SDHB mutation carriers with malignant pheochromocytoma respond better to CVD.
L. Fishbein, Sivan Ben-Maimon, S. Keefe, K. Cengel +5 more
2017Endocrine-Related Cancer49 citations Open access
Semantic Scholar
Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study
A. Hansen, C. Massard, P. Ott, N. Haas +11 more
201649 citations Open access
Semantic Scholar
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.
S. Keefe, J. Hoffman-Censits, R. Cohen, R. Mamtani +16 more
2016Annals of Oncology47 citations Open access
Semantic Scholar
Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).
J. Vuky, A. Balar, D. Castellano, P. O'Donnell +11 more
201844 citations
Semantic Scholar
Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy.
B. Baumann, Thomas J. Guzzo, Ji-Wei He, David J. Vaughn +8 more
2011International Journal of Radiation Oncology, Biology, Physics42 citations
Semantic Scholar
Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation.
Benjamin Goldsmith, Brian C. Baumann, Ji-Wei He, K. Tucker +8 more
2014International Journal of Radiation Oncology, Biology, Physics40 citations
Semantic Scholar
Targeting Vascular Endothelial Growth Factor Receptor in Thyroid Cancer: The Intracellular and Extracellular Implications
S. Keefe, Marc A. Cohen, M. Brose
2010Clinical Cancer Research40 citations Open access
Semantic Scholar
Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.
U. Matulonis, R. Shapira, A. Santin, A. Lisyanskaya +15 more
202039 citations
Semantic Scholar
Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
S. Nishio, Koji Matsumoto, K. Takehara, N. Kawamura +13 more
2020Cancer Science39 citations Open access
Semantic Scholar
LONGITUDINAL ASSESMENT OF VASCULAR FUNCTION WITH SUNITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
A. Catino, R. Hubbard, J. Chirinos, R. Townsend +15 more
2018Circulation: Heart Failure35 citations Open access
Semantic Scholar
Phase II trial of sorafenib in patients with advanced thyroid cancer.
S. Keefe, A. Troxel, S. Rhee, Kanchan Puttaswamy +4 more
2011Journal of Clinical Oncology35 citations
Semantic Scholar
Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results
M. Atkins, E. Plimack, I. Puzanov, M. Fishman +10 more
201632 citations Open access
Semantic Scholar
A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy.
B. Baumann, T. Guzzo, Ji-Wei He, S. Keefe +6 more
2012Journal of Clinical Oncology32 citations
Semantic Scholar
ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer.
D. Lorusso, N. Colombo, R. Coleman, L. Randall +16 more
202029 citations
Semantic Scholar
Bladder cancer patterns of pelvic failure: Implications for adjuvant radiation therapy.
B. Baumann, T. Guzzo, Ji-Wei He, D. Vaughn +8 more
2012Journal of Clinical Oncology28 citations
Semantic Scholar
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
K. Patterson, V. Prabhu, R. Xu, Hao-Jie Li +8 more
2019European Urology Oncology27 citations Open access
Semantic Scholar
ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.
I. Vergote, J. Sehouli, V. Salutari, P. Zola +14 more
2019Journal of Clinical Oncology27 citations
Semantic Scholar
Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
M. Atkins, Shilpa Gupta, T. Choueiri, D. McDermott +6 more
2015Journal of Immunotherapy for Cancer25 citations Open access
Semantic Scholar
Reaffirming and Clarifying the American Society of Clinical Oncology’s Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment
J. Weber, Laura A. Levit, P. Adamson, S. Bruinooge +10 more
2016Journal of Clinical Oncology24 citations Open access
Semantic Scholar
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
V. Narayan, R. Mamtani, S. Keefe, T. Guzzo +2 more
2015Cancer research and treatment : official journal of Korean Cancer Association24 citations Open access
Semantic Scholar
Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy
Melody Ju, G. Kao, David Steinmetz, S. Chandrasekaran +5 more
2014Cancer Biology & Therapy24 citations Open access
Semantic Scholar
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
H. Kang, K. Tan, S. Keefe, D. Heitjan +4 more
2013AJR. American journal of roentgenology24 citations
Semantic Scholar
A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer
V. Makker, N. Colombo, A. Herráez, A. Santin +20 more
2021Gynecologic Oncology22 citations
Semantic Scholar
A phase II trial of an oral CDK 4/6 inhibitor, PD0332991, in advanced breast cancer.
A. DeMichele, A. Clark, D. Heitjan, S. Randolph +11 more
201319 citations
Semantic Scholar
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
J. Ledermann, R. Shapira-Frommer, A. Santin, A. Lisyanskaya +20 more
2023Gynecologic Oncology17 citations Open access
Semantic Scholar
KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
B. Monk, N. Colombo, K. Tewari, C. Dubot +14 more
2023Journal of Clinical Oncology16 citations
Semantic Scholar
Validation of a coding algorithm to identify bladder cancer and distinguish stage in an electronic medical records database
R. Mamtani, K. Haynes, B. Boursi, F. Scott +5 more
2014Cancer Epidemiology, Biomarkers and Prevention15 citations Open access
Semantic Scholar
KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC).
A. Kamat, J. Bellmunt, T. Choueiri, K. Nam +10 more
201613 citations
Semantic Scholar
ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.
T. van Gorp, M. Mirza, A. Lortholary, D. Cibula +16 more
2021Journal of Clinical Oncology12 citations
Semantic Scholar
KEYNOTE-826: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Pembrolizumab Plus Chemotherapy for First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
R. Shapira-Frommer, J. Alexandre, B. Monk, T. Fehm +8 more
2019Journal of Clinical Oncology11 citations Open access
Semantic Scholar
Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer
E. Høgdall, C. Høgdall, Thao T. Vo, Wei Zhou +9 more
2020International Journal of Gynecological Cancer10 citations Open access
Semantic Scholar
Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible
T. Freshwater, Haojie Li, C. Valiathan, Mengyao Li +4 more
2019American Journal of Clinical Oncology10 citations
Semantic Scholar
Chemotherapy treatments, costs of care, and survival for elderly patients diagnosed with cervical cancer: an observational study
C. Shao, Jing-Hua He, K. Stein, S. Keefe
2020Current Medical Research and Opinion9 citations
Semantic Scholar
ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.
C. Marth, C. Vulsteke, M. Rubio Pérez, V. Makker +11 more
2020Journal of Clinical Oncology9 citations
Semantic Scholar
Association between stromal/TGF-β/EMT gene expression signature and response to pembrolizumab monotherapy in cisplatin-ineligible patients with locally advanced (unresectable) or metastatic urothelial carcinoma.
P. Grivas, D. Castellano, P. O'Donnell, R. Cristescu +10 more
2019Journal of Clinical Oncology9 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Colombo×10
Invite
N. Colombo — researcher profile on SciRah
R. Shapira-Frommer×8
Invite
R. Shapira-Frommer — researcher profile on SciRah
P. Grivas×7
Invite
P. Grivas — researcher profile on SciRah
E. Plimack×7
Invite
E. Plimack — researcher profile on SciRah

×7

Invite

R. de Wit — researcher profile on SciRah

Invite

K. Hasegawa — researcher profile on SciRah

S. Malkowicz×7

Invite

S. Malkowicz — researcher profile on SciRah

Invite

A. Balar — researcher profile on SciRah

D. Castellano×6

Invite

D. Castellano — researcher profile on SciRah

P. O'Donnell×6

Invite

P. O'Donnell — researcher profile on SciRah

Invite

N. Hahn — researcher profile on SciRah

Invite

D. Bajorin — researcher profile on SciRah